Image_4_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.TIF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Table_9_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Table_14_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Table_15_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Table_2_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Image_2_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.TIF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Table_4_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Table_10_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Image_1_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.TIF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Table_3_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

Table_7_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT_1A receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Reduction of IL-8 is associated with a relevant decrease of GBA2 expression in CF bronchial cells. by Nicoletta Loberto (2224150)

Permanent gas data (CO, CO₂, CH₄ and H₂) from the pyrolysis of banagrass S3 as a function of temperature and vapor residence time, presented as wt%... by Trevor James Morgan (787777)

Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”

Time-dependent decreases in beclin-1 (A), Atg5 (B), and SIRT1 (C) protein expression in N2a cells exposed to exogenous Aβ1–42 (10μ μM). by Hye Rin Lee (616252)

Data_Sheet_1_Leptin Increases Expression of 5-HT2B Receptors in Astrocytes Thus Enhancing Action of Fluoxetine on the Depressive Behavior Induced by Sleep Deprivation.docx by Xiaowei Li (620087)

“…In this study, we discovered: (i) that activation of NLRP3 inflammasome was involved in the depressive-like behaviors induced by SD; (ii) decrease in BDNF following SD required the activation of NLRP3 inflammasomes; (iii) leptin augmented the anti-depressive action of fluoxetine through an increase in expression of astrocytic 5-HT_2B receptors. …”